Jun 14 |
ASLAN Pharmaceuticals announces plan to implement ADS ratio change
|
Jun 14 |
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
|
Jun 4 |
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
|
Jun 4 |
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
|
May 7 |
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
|
May 2 |
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
|
Apr 24 |
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
|
Apr 22 |
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
|
Apr 19 |
ASLAN Pharmaceuticals announces receipt of Nasdaq notice
|
Apr 19 |
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
|